A new drug shows promise in combating Parkinson’s disease while minimizing unwanted side effects.
According to the study, it was found that patients who took at least 400 mg of levodopa a day for longer periods, once a day Tavapadon, relieved symptoms including stiffness, coordination, tremor and exercise-long periods and were experiencing “movement fluctuations” and recovered the medication in the study.
So far, levodopa has been the standard first-line treatment for Parkinson’s patients.
Research shows
Levodopa is converted into dopamine in the brain and targets D2/D3/D4 dopamine receptors – which have been linked to side effects, including sleep disorders, hallucinations, impulse control behavior disorders, weight gain, swelling of the legs, swelling of the legs and changes in blood pressure.
A new drug shows promise in combating Parkinson’s disease while minimizing unwanted side effects. (iStock)
According to Hubert H. Fernandez, MD, lead study author and director of the Cleveland County Neurological Restoration Center, Hubert H. Fernandez, MD, Tavapadon (by working through mimicking dopamine and targeting D1/D5 receptors) has the same benefits as Levodopa without adverse reactions.
Dance relieves depression symptoms in Parkinson’s patients, new research shows
Fernandez told Fox News Digital Numbers that it offers patients another option to alleviate their movement fluctuations, which are often experienced in Parkinson’s disease from left to late (by our best medication in Parkinson’s so far). ”
“This global, multicenter pivotal trial showed that patients placed in Tavapadon had less ‘on-time’ and ”””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””””’
Tavapadon is a pill once a day, while the current first-line drug, L-dopa, requires three pills per day. (iStock)
In this study, the researchers measured impulse control behavioral disorders, daytime excessive lethargy, blood pressure changes, and weight changes in the patients, and found that adverse reactions associated with Tavapadon were no different from those who received the placebo.
“Of course, this is a short-term study and we need to wait for our long-term study to really believe that our initial observations are still correct,” Fernandez noted. “We are very encouraged despite this.”
“Whenever it is used, whether it is in the beginning or as an adjuvant therapy for levodopa, we think it is a general benefit.”
Researchers presented the results of the Tempo 3 trial at the American College of Neurology (AAN) held earlier this month in San Diego.
For those who have recently been diagnosed with less severe motor symptoms, Fernandez recommends that once-daily doses of Tavapadon may replace three times the daily dose of levodopa.
“It provides patients with an option to alleviate their motor fluctuations, which are often experienced in Parkinson’s disease from left to late (we are by far the best medication in Parkinson’s disease),” said one researcher. (iStock)
“If they need levodopa at some point, they need lower doses and lower frequency, reducing their likelihood of developing motor fluctuations and movement disorders and other side effects,” he noted in the release.
For those with more advanced Parkinson’s disease, Tavapadon can be paired with Levodopa.
In Brett Favre’s Parkinson diagnosis, neurologists discuss how concussion affects risks
“So whenever it is used, whether it is in the beginning or as an adjuvant therapy for levodopa, we think it is a general benefit,” Fernandez added.
Recent research has found that Parkinson’s case is expected to surge by 2050, affecting as many as 25 million people worldwide.
The biggest increase will affect people of age 80 years old and aboveThey noted that by 2050, cases in that age group are expected to increase by 196%.
Among those aged 80 and over, Parkinson’s case is expected to increase by 196% by 2050. (iStock)
As a result of long-term trials, Abbvie, a manufacturer of Tavapadon, will soon file an application with the Food and Drug Administration to approve the drug.
“The FDA will then review the application – from there, they can approve the use of it, ask more questions that may not be clear, or ask for other research or extensions to validate some results,” Fernandez said.
Click here to get the Fox News app
He added: “We hope that this new generation of dopamine agonists – more selective in dopamine receptor stimulation and given only once a day – will significantly improve the symptomatic treatment of PD symptoms in the early, mid- and late stages of the disease.”
Click here to sign up for our health newsletter
Dr. Mary Ann Picone, director of medical director at the MS Medical Center in Teaneck, New Jersey, was not involved in the study, but called the results “very interesting and encouraging, a new tool to improve the quality of life for people with Parkinson’s disease.”
Recent research has found that Parkinson’s case is expected to surge by 2050, affecting as many as 25 million people worldwide.
“One of the main limitations of long-term use of dopamine is wearing and requires more frequent use,” Picone told Fox News Digital.
“The use of dopamine agonists helps prolong the long-term benefits of dopamine. A decrease in the benefits of dopamine can lead to ‘freezing’, or increased stiffness and difficulty in the patient.”
For more health articles, visit www.foxnews.com/health
“This new therapy will target different receptors and allow more ‘on’ time, but without involuntary movement disorders (uncontrolled movement) … can interfere with function.”
